Cure8 news brief
If you or someone you care for uses or may use VELSIPITY (etrasimod) for ulcerative colitis, local manufacturing and priority review in China could improve drug supply, availability, and potentially lower costs. The update also signals ongoing commercial rollout and reimbursement talks that affect access.
Adults with moderately to severely active ulcerative colitis, patients on or considering S1P modulators, gastroenterologists, IBD clinic teams, and health policy/program managers in China and the Asia-Pacific region.
Everest Medicines says China’s NMPA CDE accepted and granted Priority Review to a localized manufacturing application for VELSIPITY (etrasimod arginine tablets).
The company reports plans to start localized production at its Jiashan facility in 2027 to boost supply capacity (up to 50 million tablets/year), lower costs, and support commercialization after the drug’s Feb 2026 NMPA approval for adults with moderately to severely active ulcerative colitis.
The release highlights prior clinical data and guideline inclusions cited by the company (ECCO, AGA, ACG, APAGE) and mentions long-term efficacy and safety data presented at professional meetings. It also notes ongoing NRDL reimbursement negotiations in China. This note is grounded in the company's announcement and related metadata from the provided article.
This is a company press release about regulatory and manufacturing progress. It summarizes prior clinical presentations and guideline inclusions but does not present new independent clinical data. Localized manufacturing and Priority Review are regulatory/operational milestones that may affect supply timing but are not clinical efficacy or safety findings.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
This study models comparative cost-effectiveness across many advanced therapy sequences for moderate–severe ulcerative colitis in Japan; its findings could influence how health systems and clinicians consider first- and...
This study will collect real-world data on etrasimod, an oral S1P receptor modulator, in people with ulcerative colitis, using patient-reported symptom measures over one year — information that may help patients and...
This abstract reports that etrasimod improved multiple measures of disease activity versus placebo in patients who had inadequate response to conventional UC therapies, indicating it may be a useful first-line advanced...
